Latest Innovation News

Genesis Energy’s 2025 Investor Day confirms its strategy and earnings growth remain firmly on track, anchored by a substantial renewable pipeline and robust capital management.

Fisher & Paykel Healthcare reported a robust 14% revenue increase and a 39% jump in net profit for the first half of fiscal 2026, driven by strong clinical adoption and product innovation.

Osteopore Limited has drawn an additional A$250,000 under the first tranche of its redeemable convertible notes, continuing its steady capital raise to support growth and innovation.

Locate Technologies has successfully raised NZ$1 million to bolster its balance sheet ahead of its planned listing on the New Zealand Exchange this December. The capital raise reflects strong investor confidence as the company prepares to transition its logistics technology platform to a new market.

Locate Technologies moves closer to shifting its listing from the ASX to the New Zealand Exchange, completing a NZ$1 million share offer as part of its capital restructure.

Zelira Therapeutics has received a $1.07 million cash refund under Australia’s R&D Tax Incentive Scheme, reinforcing its funding for ongoing clinical trials and product development. The company has also repaid a prior loan advanced against this claim, positioning it for continued growth in cannabinoid-based medicines.

Macquarie Technology Group unveiled ambitious plans to expand its AI-optimised data centre footprint, supported by a $450 million debt facility and strong growth across its cloud, government cybersecurity, and telecom divisions.

ABx Group has successfully raised over $6 million through a share placement to fund rapid development of its Deep Leads rare earth project and ALCORE pilot plant in Tasmania.

New Frontier Minerals has raised $2.25 million to fast-track development of its Harts Range rare earths project, leveraging a promising new processing technology from Metallium Ltd. The capital injection supports an imminent drilling campaign and advances a mining lease application in Queensland.

Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.

Legacy Minerals reports significant progress across its exploration portfolio, with Earth AI completing a major earn-in at Fontenoy and Rio Tinto gearing up for a deep geophysical survey at Thomson. Ongoing drilling and partner commitments highlight the company’s potential for new discoveries.

Mesoblast has achieved a landmark FDA approval for RYONCIL, the first allogeneic mesenchymal stromal cell therapy, driving strong commercial momentum and advancing a robust pipeline targeting inflammatory diseases.